LeonaBio, Inc. (LONA)
NASDAQ: LONA · Real-Time Price · USD
8.45
-0.17 (-1.95%)
Apr 24, 2026, 9:50 AM EDT - Market open
LeonaBio Employees
LeonaBio had 19 employees as of December 31, 2025. The number of employees decreased by 7 or -26.92% compared to the previous year.
Employees
19
Change (1Y)
-7
Growth (1Y)
-26.92%
Revenue / Employee
n/a
Profits / Employee
-$5,558,368
Market Cap
79.39M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 19 | -7 | -26.92% | 19 | 0 |
| Dec 31, 2024 | 26 | -41 | -61.19% | 26 | 0 |
| Dec 31, 2023 | 67 | 3 | 4.69% | 65 | 2 |
| Dec 31, 2022 | 64 | 29 | 82.86% | 63 | 1 |
| Dec 31, 2021 | 35 | 13 | 59.09% | 34 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Adicet Bio | 102 |
| PolyPid | 75 |
| aTyr Pharma | 60 |
| eXoZymes | 32 |
| NeurAxis | 24 |
| Gain Therapeutics | 21 |
| Filana Therapeutics | 20 |
LONA News
- 18 hours ago - LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer - GlobeNewsWire
- 4 weeks ago - LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer - GlobeNewsWire
- 4 months ago - Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition? - Benzinga
- 4 months ago - Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment - GeekWire
- 4 months ago - Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million - GlobeNewsWire
- 8 months ago - Athira Pharma Announces Reverse Stock Split - GlobeNewsWire
- 1 year ago - Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit - GlobeNewsWire